1. Home
  2. ALKT vs GLPG Comparison

ALKT vs GLPG Comparison

Compare ALKT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alkami Technology Inc.

ALKT

Alkami Technology Inc.

HOLD

Current Price

$15.61

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$28.05

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALKT
GLPG
Founded
2007
1999
Country
United States
Belgium
Employees
N/A
452
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ALKT
GLPG
Price
$15.61
$28.05
Analyst Decision
Buy
Buy
Analyst Count
7
2
Target Price
$28.57
$36.50
AVG Volume (30 Days)
1.3M
128.8K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$152,159,000.00
N/A
Revenue This Year
$21.85
N/A
Revenue Next Year
$16.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
35.68
N/A
52 Week Low
$14.11
$24.74
52 Week High
$31.18
$37.78

Technical Indicators

Market Signals
Indicator
ALKT
GLPG
Relative Strength Index (RSI) 41.73 34.12
Support Level $15.21 $27.98
Resistance Level $17.70 $34.04
Average True Range (ATR) 0.76 0.47
MACD -0.09 0.04
Stochastic Oscillator 19.27 26.41

Price Performance

Historical Comparison
ALKT
GLPG

About ALKT Alkami Technology Inc.

Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: